Antagonism between pneumococcal vaccines and COVID-19

The review examines the clinical and epidemiological links between COVID-19 and pneumonia. At the same time, both general patterns linking viral respiratory infections and bacterial infections of the lower respiratory tract are discussed, as well as recent data relating directly to COVID-19. The clinical aspects of secondary infections, the peculiarities of their etiology, course and outcomes are analyzed separately. The publication provides a short essay on the history of the development of vaccines against pneumococcal infection. The current vaccines against pneumococcal infection are described, their brief characteristics and individual characteristics are given, their clinical and immunological advantages and disadvantages are analyzed. The data on the effectiveness of vaccine prophylaxis using pneumococcal vaccine are presented. The specific and nonspecific effects of vaccine prophylaxis both at the population level and at the level of an individual organism as a whole and in particular when using vaccines against pneumococci are considered separately. Data on the putative biochemical and molecular mechanisms of these effects are presented. Based on the data presented, the need for the use of pneumococcal vaccines in the prevention of the spread of the SARS-Cov2 virus, the prevention of complications of COVID-19 and the rehabilitation of patients who have undergone this infection is substantiated. When considering the role of pneumococcal vaccines in the rehabilitation of patients who have undergone COVID-19, their potential is analyzed both in accelerating the restoration of the normal functioning of the immune system and in the prevention of superinfections. The ways of further research in this direction are outlined, which include the development of protocols for certain groups of patients with concomitant diseases and immuno-compromised contingents. In this direction, the role of a thorough and comprehensive study of the immunological and clinical indicators of this category of persons is emphasized.

1. Guan W.J., Liang W.H., Zhao Y., Liang H.R., Chen Z.S., Li Y.M. et al. Comorbidity and its impact on 1,590 patients with Covid-19 in China: A nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi: 10.1183/13993003.00547-2020.

2. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi: 10.1016/S0140-6736(20)30211-7.

3. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J. et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi: 10.1001/jama.2020.1585.

4. Lai C.C., Wang C.Y., Hsueh P.R. Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents? J Microbiol Immunol Infect. 2020;53(4):505–512. doi: 10.1016/j.jmii.2020.05.013.

5. Vila-Corcoles A., Ochoa-Gondar O., Rodriguez-Blanco T., Raga-Luria X., Gomez-Bertomeu F. Epidemiology of community-acquired pneumonia in older adults: A population-based study. Respir Med. 2009;103(2):309–316. doi: 10.1016/j.rmed.2008.08.006.

6. Rozenbaum M.H., Pechlivanoglou P., Van Der Werf T.S., Lo-Ten-Foe J.R., Postma M.J., Hak E. The Role Of Streptococcus Pneumoniae In CommunityAcquired Pneumonia Among Adults In Europe: A Meta-Analysis. Eur J Clin Microbiol Infect Dis. 2013;32(3):305–316. Doi: 10.1007/S10096-012-1778-4.

7. Mandell L.A. Epidemiology and etiology of community-acquired pneumonia. Infect Dis Clin North Am. 2004;18(4):761–776. doi: 10.1016/j.idc.2004.08.003.

8. De Blasio A., Chioni L., Adorni G. Differential Diagnosis of Types of Pneumonia in the Elderly. In: Vargas N., Esquinas A. (eds.). Covid-19 Airway Management and Ventilation Strategy for Critically Ill Older Patients. Springer, Cham; 2020. Available at: http://link.springer.com/10.1007/978-3-030-55621-1_5.

9. Kostinov M.P. (ed.). Fundamentals of Immune Rehabilitation in New Coronavirus Infection (COVID-19). Moscow: Group MDV; 2020. (In Russ.)

10. Abelenda-Alonso G., Rombauts A., Gudiol C., Meije Y., Ortega L., Clemente M. et al. Influenza and bacterial coinfection in adults with communityacquired pneumonia admitted to conventional wards: Risk factors, clinical features, and outcomes. Open Forum Infect Dis. 2020;7(3):ofaa066. doi: 10.1093/ofid/ofaa066.

11. Verma A.K., Bansal S., Bauer C., Muralidharan A., Sun K. Influenza Infection Induces Alveolar Macrophage Dysfunction and Thereby Enables Noninvasive Streptococcus pneumoniae to Cause Deadly Pneumonia. J Immunol. 2020;205(6):1601–1607. doi: 10.4049/jimmunol.2000094.

12. Mimura K., Kimura S., Kajiwara C., Nakakubo S., Schaller M.A., Ishii Y. et al. Pneumococcal conjugate vaccine modulates macrophage-mediated innate immunity in pneumonia caused by Streptococcus pneumoniae following influenza. Microbes Infect. 2020;22(8):312–321. doi: 10.1016/j.micinf.2019.12.005.

13. Kostinov M.P., Kostinov A.M., Pakhomov D.V., Polishchuk V.B., Kostinova A.M., Shmitko A.D., Tarasova A.A. Efficacy of pneumococcal vaccine in immunocompetent and immunocompromised patients Zhurnal mikrobiologii, ehpidemiologii i immunobiologii = Journal of Microbiology, Epidemiology and Immunobiology. 2019;(5):72–83. (In Russ.) doi: 10.36233/0372-9311-2019-5-72-83.

14. Shmelev E.I. Bacterial immunocorrection in chronic bronchitis and chronic obstructive pulmonary disease. Prakticheskaya pulmonologiya = Practical Pulmonology. 2005;(1):35–38. (In Russ.) Available at: https://cyberleninka.ru/article/n/bakterialnaya-immunokorrektsiya-pri-hronicheskom-bronhitei-hronicheskoy-obstruktivnoy-bolezni-legkih.

15. Kostinov M.P., Kostinov A.M. Twenty years of clinical experience in the use of pneumococcal polysaccharide vaccine in Russia in children with health disorders (information material for preparing a lecture). Infektsionnyye bolezni: novosti, mneniya, obucheniye = Infectious Diseases: News, Opinions, Education. 2019;8(2):118–128. (In Russ.) doi: 10.24411/2305-3496-2019-12015.

16. Kostinov M.P., Chuchalin A.G. (eds.). Priority vaccination of respiratory infections during and after the SARS-COV-2 pandemic. Moscow: Group MDV; 2020. (In Russ.)

17. Baranov A.A., Namazova-Baranova L.S., Briko N.I., Lobzin Yu.V., Tatochenko V.K., Kharit S.M. et al. Vaccine prophylaxis of pneumococcal infection in children. Pediatricheskaya farmakologiya = Pediatric Pharmacology. 2015;12(5):550–558. (In Russ.) doi: 10.15690/pf.v12i5.1457.

18. Kostinov M.P., Pakhomov D.V., Magarshak O.O., Sukhinin M.V. Vaccine prophylaxis of pneumococcal infection as one of the causes of complications and mortality in influenza. Voprosy sovremennoy pediatrii = Current Pediatrics. 2009;8(6):131–134. (In Russ.) Available at: https://vsp.spr-journal.ru/jour/article/view/1208.

19. Chuchalin A.G., Briko N.I., Avdeev S.N., Belevsky A.S., Bilichenko T.N., Demko I.B. et al. Federal clinical guidelines for vaccine prevention of pneumococcal infection in adults. Pulmonologiya = Pulmonology. 2019;29(1):19–34. (In Russ.) doi: 10.18093/0869-0189-2019-29-1-19-34.

20. Protasov A., Kostinov M., Zhestkov A. Microbiological effect of anti-pneumococcal vaccination in COPD patients. In: 10th International Symposium On Pneumococci and Pneumococcal Diseases. Glasgow, UK, June 26–30, 2016.

21. Protasov A.D., Kostinov M.P., Zhestkov A.V., Steiner M.L., Magarshak O.O., Kostinova T.A. et al. The choice of the optimal tactics of vaccination against pneumococcal infection from immunological and clinical positions in patients with chronic obstructive pulmonary disease. Terapevticheskiy arkhiv = Therapeutic Archive. 2016;88(5):62–69. (In Russ.) doi: 10.17116/terarkh201688562-69.

22. Thevarajan I., Nguyen T.H.O., Koutsakos M., Druce J., Caly L., van de Sandt C.E. et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nature Medicine. Nature Research. 2020;26:453–455. doi: 10.1038/s41591-020-0819-2.

23. Splunter M.V., Perdijk O., Fick-Brinkhof H., Floris-Vollenbroek E.G., Meijer B., Brugman S. et al. Plasmacytoid dendritic cell and myeloid dendritic cell function in ageing: A comparison between elderly and young adult women. PLoS One. 2019;14(12):e0225825. doi: 10.1371/journal.pone.0225825.

24. Valiathan R., Ashman M., Asthana D. Effects of Ageing on the Immune System: Infants to Elderly. Scand J Immunol. 2016;83(4):255–266. doi: 10.1111/sji.12413.

25. Koch S., Larbi A., Derhovanessian E., Özcelik D., Naumova E., Pawelec G. Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun Ageing. 2008;5(1):6. doi: https://doi.org/10.1186/1742-4933-5-6.

26. Contentti C.E., Correa J. Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge. Mult Scler Relat Disord. 2020;41:102097. doi: 10.1016/j.msard.2020.102097.

27. Pan D., Sze S., Minhas J.S., Bangash M.N., Pareek N., Divall P. et al. The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. EClinicalMedicine. 2020;23:100404. doi: 10.1016/j.eclinm.2020.100404.

28. Protasov A.D., Zhestkov A.V., Lavrentieva N.E., Kostinov M.P., Ryzhov A.A. The effect of complex vaccination against pneumococcal, hemophilic type b infections and influenza in patients with chronic obstructive pulmonary disease. Zhurnal mikrobiologii, epidemiologii i immunobiologii = Journal of Microbiology, Epidemiology and Immunobiology. 2011;(4):80–84. (In Russ.) Available at: https://dlib.eastview.com/browse/doc/26145076.

29. Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H. et al. Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019. medRxiv. 2020. doi: 10.1101/2020.02.16.20023903.

30. Mathew D., Giles J.R., Baxter A.E., Oldridge D.A., Greenplate A.R., Wu J.E. et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;369(6508):eabc8511. doi: 10.1126/science.abc8511.

31. Remy K.E., Brakenridge S.C., Francois B., Daix T., Deutschman C.S., Monneret G. et al. Immunotherapies for COVID-19: lessons learned from sepsis. Lancet Respir Med. 2020;8(10):946–949. doi: 10.1016/S2213-2600(20)30217-4.

32. Rodríguez Y., Novelli L., Rojas M., De Santis M., Acosta-Ampudia Y., Monsalve D.M. et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J Autoimmun. 2020;114:102506. doi: 10.1016/j.jaut.2020.102506.